The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors

Rachel Bayley†, Forhad Ahmed†, Katie Glen, Mark McCall, Adrian Stacey and Robert Thomas*
Centre for Biological Engineering (Holywell Park), Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, Leicestershire, UK

Abstract

Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a process would need to be extremely efficient for economic viability given a relatively low value product and high (2 × 10^12) cell dose. Therefore, the aim of these studies was to define the productivity of an industry standard stirred-tank bioreactor and determine engineering limitations of commercial red blood cells production. Cord blood derived CD34+ cells were cultured under erythroid differentiation conditions in a stirred micro-bioreactor (Ambr™). Enucleated cells of 80% purity could be created under optimal physical conditions: pH 7.5, 50% oxygen, without gas-sparging (which damaged cells) and with mechanical agitation (which directly increased enucleation). O₂ consumption was low (~5 × 10⁻⁸ µg/cell.h) theoretically enabling erythroblast densities in excess of 5 × 10⁸/ml in commercial bioreactors and sub-10 l/unit production volumes. The bioreactor process achieved a 24% and 42% reduction in media volume and culture time, respectively, relative to unoptimized processing. However, media exchange limited productivity to 1 unit of erythroblasts per 500 l of media. Systematic replacement of media constituents, as well as screening for inhibitory levels of ammonia, lactate and key cytokines did not identify a reason for this limitation. We conclude that the properties of erythroblasts are such that the conventional constraints on cell manufacturing efficiency, such as mass transfer and metabolic demand, should not prevent high intensity production; furthermore, this could be achieved in industry standard equipment. However, identification and removal of an inhibitory mediator is required to enable these economies to be realized.

Keywords blood; manufacture; red cell; erythrocyte; culture; bioreactor; cost; productivity

1. Introduction

Blood transfusions are one of the most common clinical interventions worldwide with ~21 million donated blood components transfused each year in the USA alone. Increasing demand due to aging populations, challenges of adventitious agent screening, or requirement for specific immuno-phenotypes, has created a growing search for alternative sources to public donation. New uses for red blood cells (RBCs) such as targeted drug delivery may increase this demand further (Bourgeaux et al., 2016). There is evidence that transfusion of homogenously young RBCs may have clinical benefit by decreasing the transfusion frequency of chronically transfused patients (Bosman, 2013; Luten et al., 2008). One proposed solution to these issues is the manufacture of RBC from stem or progenitor cells potentially providing an unlimited supply of cells in an optimal age distribution (Zeuner et al., 2012).

Anucleate RBCs have successfully been produced in vitro from a variety of cell sources including haematopoietic stem cells such as cord blood CD34+ cells, adult mobilised peripheral blood, and bone marrow CD34+ cells (Neildez-Nguyen et al., 2002; Giarratana et al., 2005; Miharada et al., 2006; Fujimi et al., 2008; Giarratana et al., 2011). Recently, approaches using human pluripotent cells, both induced and embryonic, have also been reported, although challenges with control of appropriate lineage and development of adult phenotype remain (Qiu et al., 2008; Lu et al., 2008; Lapillonne et al., 2010; Dias et al., 2011; Chang et al., 2011; Kobari et al., 2012). Due to the exceptionally high numbers of erythroblast stage cells required to be maintained in viable culture in any candidate production process, common late stage manufacturing challenges exist irrespective of initial cell source.

Challenges associated with the scale-up of any cell culture bioprocess include maintaining consistency, quality and quantity of the cell product whilst minimizing cost of production (Rousseau et al., 2014; Timmins and Nielsen, 2009). This is particularly fraught with RBC production due to the requirement for relatively extreme process intensification whilst avoiding detrimental effects on cells, and where there is little understanding of the sensitivities of each stage of the progressively maturing erythroid phenotype to common bioprocess operations. In particular, robust erythroblast enucleation to produce reticulocytes and then fully mature RBCs has been
problematic in vitro and the mechanisms still remain to be fully elucidated (Kingsley et al., 2004; Lee et al., 2004). With respect to cost of production, RBC is an example of a high dose product where cost of goods reduction is a priority for commercial viability. It has been estimated that one unit of cultured RBCs would cost $8000–15,000 to produce using current processes, compared to $200–230 for one unit of donated blood (Zeuner et al., 2012). The primary reason for this high cost is expensive media components required for in vitro differentiation and maturation multiplied by large culture volumes. This has led to calls for research to identify and address the fundamental barriers to efficient production of erythroid cells (Rousseau et al., 2014).

Cost effective production of RBCs will require high density cell culture. Conventional culture densities are considered high at 1 × 10⁷ cells/ml, yet this would still require a 200-l final volume to produce a single unit or 2 × 10¹² cells. To achieve a final harvest of 2 × 10¹² cells in a 5-l volume will require a density of 4 × 10⁸ cells/ml. Neither of these volumes accounts for the proportionality of the limitations, to enable the productivity of RBC manufacture at scale, and the nature of the limitations, to enable the manufactured blood field to move forward. In order to address this, we have used a model system of differentiation of CB CD34+ cells to RBCs in a ml-scale stirred tank bioreactor system.

It has previously been shown that CB CD34+ cells can proliferate and differentiate to erythroid cells in a scaled down version of industry standard production equipment, the stirred microbioreactor system, Ambr™ (Glen et al., 2013; Hsu et al., 2012; Ratcliffe et al., 2012). In the present study, the intensification limits (bioreactor operation, gas transfer, media usage) of cells in such standard equipment were explored to determine current productivity and limiting mechanisms with respect to key criteria: cost of goods (system volume, media volume per cell and process time per cell) and quality (enucleated cells). This is important to allow the field to take an informed approach to address the engineering and scientific challenges that need to be overcome to generate an economically viable product.

2. Materials and methods

2.1. CD34+ cell culture

Fresh umbilical cord-derived mononuclear cells were supplied by the Anthony Nolan Cell Therapy Centre (http://www.anthonynolan.org/clinicians-and-researchers/cord-blood-services) with informed consent and NREC ethical approval. CD34+ cells were isolated via positive selection using CD34 antibody-labelled microbeads as per the manufacturer’s instructions (Miltenyi Biotec, Germany). Mixed donor CD34+ cells (>70% purity) were cryopreserved prior to cell culture. On thaw, CD34+ cells were cultured in accordance with a three-stage protocol as described previously (Griffiths et al., 2012). Briefly, cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Source BioScience) containing 3% (v/v) AB Serum (Sigma), 2 mg/ml human serum albumin (Irvine Scientific, USA), 10 μg/ml Insulin (Sigma), 3 U/ml heparin (Sigma), 500 μg/ml iron saturated Transferrin (R&D Systems). In the first stage (days 0–8) this was supplemented with 10 ng/ml SCF, 1 ng/ml interleukin (IL)-3 and 3 U/ml erythropoietin (EPO); in the second stage (days 8–11) with 10 ng/ml stem cell factor (SCF), 3 U/ml EPO and in the final stage (days 11–20) with 3 U/ml EPO. Cells were cultured in tissue culture flasks at 37°C, 5% CO₂ for 3 days, after which cells were either maintained in control static culture or transferred to the Ambr bioreactor system (TAP Biosystems, Royston, UK). Bioreactors were preconditioned as described previously (Glen et al., 2013) and vessels were gassed either using a sparge tube or via the vessel headspace if nonsparged. 0.1% Pluronic F-68 (Gibco, Paisley, UK), impeller speed, pH, and O₂ (percentage of atmospheric), were varied as specified in results.

2.2. Culture analysis

2.2.1. Cell count and viability

Online cell counting and viability was measured using a Vi-Cell XR (Beckman Coulter, USA). Population doublings (PD) were calculated as follows:

\[
PD = \left\{ \left[ \frac{\log(CN)}{\log(CN_0)} \right] \times 3.33 \right\}
\]

\[
CN = start\; cell\; number, \; and \; CN = end\; cell\; number.
\]

2.2.2. Flow cytometry of erythroid lineage markers

Samples were analysed using a BD FACScanto™ II flow cytometer (BD Biosciences) and gated against specific isotype controls to determine percentage positive cells.

2.2.3. Assessment of cell morphology

Cells were cultured in accordance with a three-stage protocol as described previously (Griffiths et al., 2012). Briefly, cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Source BioScience) containing 3% (v/v) AB Serum (Sigma), 2 mg/ml human serum albumin (Irvine Scientific, USA), 10 μg/ml Insulin (Sigma), 3 U/ml heparin (Sigma), 500 μg/ml iron saturated Transferrin (R&D Systems). In the first stage (days 0–8) this was supplemented with 10 ng/ml SCF, 1 ng/ml interleukin (IL)-3 and 3 U/ml erythropoietin (EPO); in the second stage (days 8–11) with 10 ng/ml stem cell factor (SCF), 3 U/ml EPO and in the final stage (days 11–20) with 3 U/ml EPO. Cells were cultured in tissue culture flasks at 37°C, 5% CO₂ for 3 days, after which cells were either maintained in control static culture or transferred to the Ambr bioreactor system (TAP Biosystems, Royston, UK). Bioreactors were preconditioned as described previously (Glen et al., 2013) and vessels were gassed either using a sparge tube or via the vessel headspace if nonsparged. 0.1% Pluronic F-68 (Gibco, Paisley, UK), impeller speed, pH, and O₂ (percentage of atmospheric), were varied as specified in results.

2.2. Culture analysis

2.2.1. Cell count and viability

Online cell counting and viability was measured using a Vi-Cell XR (Beckman Coulter, USA). Population doublings (PD) were calculated as follows:

\[
PD = \left\{ \left[ \frac{\log(CN)}{\log(CN_0)} \right] \times 3.33 \right\}
\]

\[
CN = start\; cell\; number, \; and \; CN = end\; cell\; number.
\]

2.2.2. Flow cytometry of erythroid lineage markers

Cells were sampled to FACS tubes (1 × 10⁵/tube) and incubated with preconjugated antibodies CD34-FITC (BD Biosciences, San Jose, CA, USA), CD235a-PE (BD Biosciences) and DRAQ5 (nuclear stain; BioStatus, Loughborough, UK) for 20 min at room temperature (RT). CD235a+/DRAQ5- cells were classified as enucleated. Samples were analysed using a BD FACScanto™ II flow cytometer (BD Biosciences) and gated against specific isotype controls to determine percentage positive cells.

2.2.3. Assessment of cell morphology

Cells were cultured in accordance with a three-stage protocol as described previously (Griffiths et al., 2012). Briefly, cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Source BioScience) containing 3% (v/v) AB Serum (Sigma), 2 mg/ml human serum albumin (Irvine Scientific, USA), 10 μg/ml Insulin (Sigma), 3 U/ml heparin (Sigma), 500 μg/ml iron saturated Transferrin (R&D Systems). In the first stage (days 0–8) this was supplemented with 10 ng/ml SCF, 1 ng/ml interleukin (IL)-3 and 3 U/ml erythropoietin (EPO); in the second stage (days 8–11) with 10 ng/ml stem cell factor (SCF), 3 U/ml EPO and in the final stage (days 11–20) with 3 U/ml EPO. Cells were cultured in tissue culture flasks at 37°C, 5% CO₂ for 3 days, after which cells were either maintained in control static culture or transferred to the Ambr bioreactor system (TAP Biosystems, Royston, UK). Bioreactors were preconditioned as described previously (Glen et al., 2013) and vessels were gassed either using a sparge tube or via the vessel headspace if nonsparged. 0.1% Pluronic F-68 (Gibco, Paisley, UK), impeller speed, pH, and O₂ (percentage of atmospheric), were varied as specified in results.

2.2. Culture analysis

2.2.1. Cell count and viability

Online cell counting and viability was measured using a Vi-Cell XR (Beckman Coulter, USA). Population doublings (PD) were calculated as follows:

\[
PD = \left\{ \left[ \frac{\log(CN)}{\log(CN_0)} \right] \times 3.33 \right\}
\]

\[
CN = start\; cell\; number, \; and \; CN = end\; cell\; number.
\]

2.2.2. Flow cytometry of erythroid lineage markers

Cells were sampled to FACS tubes (1 × 10⁵/tube) and incubated with preconjugated antibodies CD34-FITC (BD Biosciences, San Jose, CA, USA), CD235a-PE (BD Biosciences) and DRAQ5 (nuclear stain; BioStatus, Loughborough, UK) for 20 min at room temperature (RT). CD235a+/DRAQ5- cells were classified as enucleated. Samples were analysed using a BD FACScanto™ II flow cytometer (BD Biosciences) and gated against specific isotype controls to determine percentage positive cells.

2.2.3. Assessment of cell morphology

Cells were cultured in accordance with a three-stage protocol as described previously (Griffiths et al., 2012). Briefly, cells were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) (Source BioScience) containing 3% (v/v) AB Serum (Sigma), 2 mg/ml human serum albumin (Irvine Scientific, USA), 10 μg/ml Insulin (Sigma), 3 U/ml heparin (Sigma), 500 μg/ml iron saturated Transferrin (R&D Systems). In the first stage (days 0–8) this was supplemented with 10 ng/ml SCF, 1 ng/ml interleukin (IL)-3 and 3 U/ml erythropoietin (EPO); in the second stage (days 8–11) with 10 ng/ml stem cell factor (SCF), 3 U/ml EPO and in the final stage (days 11–20) with 3 U/ml EPO. Cells were cultured in tissue culture flasks at 37°C, 5% CO₂ for 3 days, after which cells were either maintained in control static culture or transferred to the Ambr bioreactor system (TAP Biosystems, Royston, UK). Bioreactors were preconditioned as described previously (Glen et al., 2013) and vessels were gassed either using a sparge tube or via the vessel headspace if nonsparged. 0.1% Pluronic F-68 (Gibco, Paisley, UK), impeller speed, pH, and O₂ (percentage of atmospheric), were varied as specified in results.
The productivity limit of manufactured blood cell therapy

Radnor, PA, USA) and mounted with mounting medium and a glass coverslip. Slides were examined by bright field microscopy using an Eclipse Ti (Nikon, Tokyo, Japan) at 40× magnification.

2.2.4. High-performance liquid chromatography for haemoglobin expression

High-performance liquid chromatography (HPLC) globin chain separation was performed using a protocol modified from Lapillonne et al. (2010). Cells (10⁶) were centrifuged at 300 × gav for 6 min at RT, lysed in 50 μl water, and stored at −80°C. On thaw, samples were centrifuged at 13,000 × gav at 4°C for 10 min and the lysates collected. Supernatant (10 μl) was injected onto a 1.0 × 250 mm C4 column (Phenomenex, Macclesfield, UK) with a 42% to 56% linear gradient between mixtures of 0.1% trifluoroacetic acid in water (Buffer A) and 0.1% trifluoroacetic acid in acetonitrile (Buffer B) at flow rate of 0.05 mL/min for 50 min (Dionex HPLC Ultimate 3000 system; Thermo Fisher Scientific, Camberley, UK). The column temperature was 50°C and the UV detector set at 220 nm.

2.2.5. Cytokine analysis

Ten analytes [IL-1β, IL-2, IL-4, IL-6, IL-10, interferon-γ, tumour necrosis factor-α, transforming growth factor (TGF)-β1, TGF-β2, and TGF-β3] were quantified from cell culture supernatant with the Bio-Plex Pro™ Human Cytokine Group I, 7-plex assay kit and the Bio-Plex Pro TGF-β, 3-plex assay kit (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer’s instructions. Data were acquired using a Bio-Plex-200 suspension array system and concentrations calculated with Bio-Plex Manager software 6.1 on a Bio-Plex® MAGPIX™ instrument using a standard curve derived from a recombinant cytokine standard (supplied by the manufacturer).

2.2.6. O₂ consumption rate

Erythroblasts were taken at a series of time-points and O₂ consumption assessed using an O₂ sensitive phosphorescence (Excitation = 380 ± 20 nm / Emission = 650 ± 50 nm) and O₂ consumption (mg/cell.h) was calculated based on a 0.9% solubility of O₂ in saline solution at 37°C under 1 atmospheric pressure (6.7 mg O₂/l). Maximum supportable cell density in commercial scalable systems was calculated using the formula:

\[
\text{Cell density} = \frac{K_{la} \times (C^* - C)}{R}
\]

Where \(K_{la}\) = reported mass transfer coefficient of system (l/h), \(C^*\) = saturation O₂ concentration (6.7 mg/l), C = maintenance O₂ concentration (3.35 mg/l), and R = O₂ consumption (mg/cell.h).

2.2.7. System medium per cell volumetric productivity analysis

Erythroblasts were taken at day 7 of culture and volumetric productivity calculated for cultures seeded in fresh medium at 3 × 10⁶/ml, 5 × 10⁶/ml and 5 × 10⁶/ml with 30% of medium replaced after 5 h:

Volumetric medium productivity (volume/cell) = Media volume used/(I.ert - I).

I (initial cell number), r (growth rate constant, h⁻¹), (t) time when growth rate becomes inhibited.

Uninhibited growth rate (r) was estimated from an exponential fit to the first 12 points of each high resolution (0.75-h counts) growth curve; time of growth inhibition (t) was determined as the point at which cell numbers deviated from extrapolation of this uninhibited model.

2.2.8. Media exhaustion studies

Erythroblasts were taken at day 7 of culture, centrifuged at 300 × gav for 6 min at RT, and resuspended in fresh culture medium at 3 × 10⁶/ml. Medium and cells were sampled hourly. Controls were cultured without intervention; experimental supplemented concentrations at 10 h were 2250 mg/l glucose, 292 mg/l glutamine, 1.5% AB serum, 5 ng/ml stem cell factor, 0.5 ng/ml interleukin-3 and 1.5 U/ml erythropoietin alone or in combination as specified in results. Amino acids (MEM Amino acids 50× solution, B6891) and phosphate (sodium phosphate monobasic, S5011) were supplemented at initial concentrations. Ammonium hydroxide and lactic acid were added to erythroblast cultures at 3 × 10⁶/ml to assess the effect on cell growth (1.3 mM, 8 mM ammonia; 5 mM, 28 mM lactate). Metabolite and nutrients were measured (or verified) using a Cedex Bio HT – Bioprocess Analyser (Roche, Switzerland).

2.3. Statistics and calculations

Statistical comparisons and design of experiment statistical design were conducted using Minitab® software. ANOVA was used to establish P-values and Tukey’s test where pairwise comparisons are stated. A minimum of \(n = 3\), was used to power statistical comparisons. Growth rate in the presence of inhibitors was calculated from an exponential fit to a six-point data series over 18 h. Growth response to supplements was calculated by the rate of deviation from extrapolated uninhibited exponential growth. Where percent enucleation is reported, it is reported to coincide with the peak system proliferation, avoiding misleadingly high percentage enucleation figures that occur as cell numbers decline.
3. Results

3.1. Erythroblast bioreactor compatibility and cell density intensification limitations

Three cell-type specific attributes, in combination with the mass transfer characteristics of a bioreactor, determine the cell density that can be supported in a culture system: tolerance to bioreactor operation (and therefore achievable mass transfer), required dissolved O2 level, and O2 uptake rate (OUR). Given the importance of culture intensification to RBC manufacture, each of these was determined for erythroblast culture.

3.1.1. Tolerance of erythroblast culture to bioreactor agitation and gassing

Mechanical agitation and gas sparging of a cell culture improves mass transfer and therefore O2 availability to cells. However, consequent mechanical stress can reduce cell viability or alter phenotype; in the case of erythroid lineage cells impeller tip speeds of >210 mm/s have been reported to be damaging (Chisti, 2001), and gassing can damage cells during bubble rupture. Further, gas damage can be exacerbated by mechanical agitation due to bubble break up and increased bubble to cell surface interface (Chisti, 2000). To test these operational factors, stir speeds of 300 revolutions/min (RPM; 157 mm/s) and 450 RPM (236 mm/s) in combination with O2 delivery via sparging through the medium or the reactor headspace were investigated for effects on cell proliferation and erythroblast maturation.

Sparged and stirred bioreactors substantially reduced erythroblast proliferation relative to static culture. This effect was increased at higher tip speed with static culture total PDs (TPD) of 15.3, decreasing to 9.9 and 6.0 at 300 and 450 RPM respectively (p ≤ 0.05). In the absence of sparging, cell proliferation in the bioreactor was improved, but still reduced relative to static culture (p ≤ 0.05). However, there was no significant difference between the different tip-speeds (300 RPM, TPD = 12.0, 450 RPM (TPD = 11.9), or any measured reduction in viability, indicating that mechanical damage was unlikely to be the reason for this remaining proliferative deficit in nonsparged bioreactors (Figure 1A). Addition of the non-ionic surfactant Pluronic-F68 (PF-68) was investigated to mitigate sparging induced damage; PF-68 restored sparged bioreactor cell growth to the level of nonsparged controls, increasing tolerable O2 input rate, and therefore increasing potential cell density (Chisti, 2000; Tharmalingam et al., 2008) (Figure 1A). Enucleated

![Figure 1](wileyonlinelibrary.com)
RBC production under each condition was evaluated by a flow cytometry assay of CD235a+/DRAQ5– cells (Figure 1B). Although protective of growth, PF-68 had a negative impact on the percentage of enucleated cells at the end of the process. This negative effect persisted when PF-68 was removed from the cultures at Day 7 (nonsparged control enucleation =68%, sparged + PF-68 = 43%, sparged + PF-68 until Day 7 = 44%; *p* ≤ 0.05). In the absence of sparging, a higher tip-speed generated substantially more enucleated product (Figure 1C). Transfer of cells from static culture to stirred culture after 19 days resulted in a rapid increase in enucleated cells demonstrating this was a direct effect of stirring on enucleation (Figure 1D).

### 3.1.2. Effect of dissolved O2 and pH level on erythroblast culture

The second erythroblast attribute necessary to determine maximum potential cell density is the dissolved O2 concentration. Both O2 and pH are reported to effect erythroid differentiation (Endo et al., 1994; McAdams et al., 1998; Sarakul et al., 2013); a matrix of pH and O2 conditions were investigated in the bioreactor system to determine relative magnitude of effect and independence.

Lower dissolved O2 greatly increased the percentage of enucleated cells (Figure 2A–C). At 25% O2 there were 78% enucleated cells, which was significantly higher than the 37% enucleated cells observed at 100% O2 (*p* ≤ 0.01). pH did not appear to be a significant factor affecting enucleation; however, pairwise comparison showed the difference between pH 7.3 and 7.5 to be close to significance (*p* = 0.14); this is in agreement with the advantage to elevated pH reported previously and our observation of the persistence of non-CD235a expressing cells at pH 7.3 (data not shown). A rise in the percentage of enucleated cells occurred with increased pH at intermediate level O2, indicating sensitivity to pH effect may be greater if dissolved O2 is not optimized (Figure 2D). pH and O2 had no significant effect on total cell proliferation or time to maximum product yield, with the TPD ranging from 12.0 to 12.6 in all cultures and the maximum product yield achieved between 17 and 20 days.

### 3.1.3. Comparison of the bioreactor produced cells to a static culture system

The established bioreactor process (pH 7.5/50% O2/450 RPM/nonsparged) was compared to the control static culture system. After 21 days in culture, a large number of mature enucleated cells were observed in both systems.
with a similar appearance to the adult donor RBC control (Figure 3A). The mature RBCs cultured in vitro were also similar in size to adult RBC (static = 8.8 μm, bioreactor = 8.3 μm, adult donor control RBC = 8.5 μm; Figure 3B). The percentage of enucleated cells was higher in bioreactor cultures (78 ± 4%) compared to static (54 ± 4%; p ≤ 0.05; Figure 3C), illustrating that increased homogeneity of enucleated cell product is achieved in the bioreactor system. Analysis of haemoglobin expression showed broad equivalence between static and bioreactor systems, and comparability to other reports from cord cells (Jin et al., 2014), including significant expression of β-globins (Figure 3D). The approximately 3 TPD deficit in proliferation in bioreactor culture relative to static culture was confirmed as previously observed (Figure 3E).

### 3.1.4. Determining specific O₂ uptake rate of erythroblasts

The maximum cell density supportable is determined by the rate of O₂ transfer into the medium in the established bioreactor process relative to the cells OUR (Xing et al., 2009). Cell OUR was monitored throughout the CD34+ to RBC differentiation process. Maximal OUR occurred at Day 6 in both static and bioreactor culture (static = 5.10 × 10⁻⁸ μgO₂/cell.h and bioreactor = 6.34 × 10⁻⁸ μgO₂/cell.h; Figure 4). After this point the OUR of cells in the bioreactor declined and reached 1.69 × 10⁻⁸ μgO₂/cell.h by Day 19. Cells in static culture had a more variable OUR following Day 6, but this still decreased to 9.11 × 10⁻⁹ μgO₂/cell.h by Day 19. The known mass transfer characteristics of commercial scale culture systems (Junker, 2004; Klockner et al., 2013; Mikola et al., 2007; Nienow et al., 2013) allows calculation of the density of erythroblasts supportable in the absence of other culture limitations, and the compatibility of those systems with constraints on bioreactor operation to increase mass transfer (identified above; Table 1). Calculations are based on consumption rates of 2.3 × 10⁻⁷ μgO₂/cell.h to allow a significant (4-fold) safety margin and indicate that cell densities in excess of 5 × 10⁹/ml (target density to allow a sub-10 l system volume/unit of 2 × 10¹² cells) should be supportable in various commercially available bioreactors.
3.2. Erythroblast medium volumetric productivity limit

Given that O₂ availability was not the primary bioreactor limitation at current culture densities the culture medium utilisation of the system was assessed. Erythroblasts from Day 6 were placed into fresh medium in bioreactors at different densities (3 × 10⁶/ml, 5 × 10⁶/ml) and with an alternate media exchange strategy (5 × 10⁶/ml with 30% exchange after 5 h) to construct high resolution growth curves. Exponential growth models of the first 9 h (12 data points) were all equivalent for growth rate (0.05 1/h) and an excellent fit (R² > 96% in all cases) indicating no significant impact of initial cell density or partial media exchange on growth rate (Figure 5A). Deviation of the data from the extrapolated model identified when growth inhibition occurred; 15.2 h (3 × 10⁶/ml), 12.4 h (5 × 10⁶/ml), 16.1 h (5 × 10⁶/ml with 30% media change after 5 h; Figure 5B). The medium replacement rate per cell produced required to keep erythroblasts in uninhibited growth was strategy dependent suggesting increased productivity from higher density culture (Table 2); this bioreactor protocol would require a lower media volume/unit produced (495 l/unit) compared to the original static laboratory protocol (662 l/unit; Table 2). Further, the bioreactor protocols maintenance of a ~13.9 h cell doubling time will only require 58% of the manufacturing facility time relative to the control static process (~24 h doubling) for any given output, with substantial cost implications.

3.3. Screening of factors limiting medium volumetric productivity

Five hundred litres of media per unit of RBCs is still at least an order of magnitude below economic levels of intensification. Inhibition of cell growth by depletion of nutrients was tested by supplementation strategies of key media component groups including glucose, glutamine, serum, cytokines (EPO, SCF and IL-3), amino acids, vitamins, and phosphate. However, this had no effect on the point at which growth inhibition occurred (Figure 6A, B). Further, only a low proportion of available glucose was depleted over the uninhibited growth period (Figure 6D); other key nutrients including iron, glutamine, and glutamate also showed negligible consumption rates over the period prior to growth inhibition (data not shown). The alternative to medium depletion is production of an inhibitory factor such as lactate or ammonia (Hassell et al., 1991); addition of exogenous supplements of either significantly inhibited growth rate in a linear fashion (p ≤ 0.05; Figure 6C). The effect of each factor was dependent on the level of the other with high lactate levels reducing the inhibitory effect of ammonia. However, to cause the observed inhibition of growth ammonia/lactate combinations in excess of 4 mM/15 mM respectively would be necessary; accumulated concentrations of endogenously produced ammonia (ND i.e. <0.3 mM) and lactate (~6 mM) at the point of growth inhibition were much lower (Figure 6D). Additionally, after a brief initial higher period, the molar ratio of lactate produced to glucose used
Figure 5. Volumetric productivity of the system is dependent on media exchange strategy (A) Cells were cultured starting at $3 \times 10^5$/ml, $5 \times 10^5$/ml and $5 \times 10^6$/ml including a 30% volume exchange after 5 h. Cells initially proliferated at a constant and equivalent rate under all conditions after which growth became inhibited. (B) The initial deviation of the cell numbers from the extrapolated exponential growth is approximately linear ($R^2 > 95$%), and can be used to approximate the time point at which growth became inhibited [Colour figure can be viewed at wileyonlinelibrary.com]

Table 2. The number of cells produced up until the time at which growth becomes inhibited can be used to calculate the volumetric productivity of each strategy if uninhibited growth were maintained. *Significantly ($p < 0.05$) different from $3 \times 10^5$/ml bioreactor

| Condition | Start cell density | Growth rate (h) | Doubling time (h) | Vol ($\ell$/unit) |
|-----------|--------------------|-----------------|------------------|------------------|
| Static Protocol | $1.00 \times 10^5$ | 0.029 | 24.25 | 662 |
| Bioreactor | $3.00 \times 10^5$ | 0.051 | 13.93 | 573 |
| Bioreactor (30% 5 h media exchange) | $5.00 \times 10^5$ | 0.051 | 13.93 | *495 |

remained constant at 0.75 with no particular deviation associated with growth inhibition (Figure 6D). Finally, cultures were screened for the production of potentially inhibitory cytokines; TGF-β, interferon-γ and tumour necrosis factor-α are prime candidates report to inhibit erythroid growth; IL-1β, IL-2, IL-4, IL-6 and IL-10 were also measured as potential feedback influences. TGF-β1 was the only factor secreted at a relatively high (ng/ml) level (Figure 6E). Dosing of exogenous TGF-β1 did decrease specific cell proliferative rate but only by 9% at 10 ng/ml, a higher dose level and lower inhibition than that observed in culture (Figure 6F). Although a substantive effect on proliferative rate was not observed, TGF-β1 did accelerate erythroblast maturation: 1 ng/ml resulted in a faster increase in CD235a expression, earlier enucleation, and ~30% reduced total proliferative capacity of cells suggesting the cytokine may be responsible for the lower proliferation/higher enucleation in the bioreactor. However, the cell specific production rate of TGF-β1 was equivalent in the static and the bioreactor system, showing a rapid decline in both systems over the first 5 h, after which it remained relatively stable (Figure 6G). Of further note, the TGF-β1 was in inactive form (bound to latency associated peptide) in either static or bioreactor culture system (≤ limit of detection 1 pg/ml i.e. ≤0.1% of total).

4. Discussion

RBCs as a manufactured product will not become economically viable unless fundamental barriers to cell culture efficiency are identified and addressed. The work here has shown that the barriers conventionally associated with high intensity cell production are not the primary limitations for the field; on the contrary, erythroblast metabolic characteristics indicate that gas mass transfer requirements, nutrient use and metabolite resistance will allow high intensity production in current industry standard bioreactor systems. Further, certain system attributes, such as mechanical stress, can be advantageously controlled to increase product purity. This understanding is necessary to inform future research that will progress the manufactured RBC field. Any adoption of nonindustry standard bioreactors, or new bioreactor design, should be based upon specific requirements of the intensified process. Defining production limits in current commercial bioreactor systems is a key starting point; such systems lower the risks and barrier to entry for product developers due to regulatory and industrial experience.

Most cell cultures are limited in absolute density by O2 transfer into the system, and this will determine the minimum volumetric footprint for the manufacturing bioreactor. The low specific OUR of the erythroblasts is at least an order of magnitude beneath those reported for common cell lines (Ruffieux et al., 1998; Goudar et al., 2011). Even given the operational constraints on actively gassing and agitating the culture media this enables potentially very high intensity production. The frequency with which media needs to be exchanged to maintain uninhibited exponential growth is therefore the primary economic constraint. This does not necessarily force a large volume for the manufacturing bioreactor, but determines the total volume of medium used in a given production run. Allowing cells to drop significantly beneath uninhibited exponential growth is grossly time, and consequently cost, inefficient due to the compounding nature of cell doubling. The observed uninhibited growth rate potential is encouraging; a 13-h erythroblast doubling time enables a 4-order of magnitude increase in cell number in a week. However, the calculated rate of media exchange required to achieve this, with many minimally
A depleted medium factor or a secreted inhibitor could exhibit the same growth limiting behaviour observed. However, we have stronger evidence for the latter given the range of supplementary strategies that do not promote further cell growth. Further, the maintenance of a constant ratio of glucose consumption to...
lactate production suggests this is not a metabolic limitation; such limits would be likely to disrupt the ratio (Zagari et al., 2013). TGF-β1 was present at high levels, and (as previously reported (Buscemi et al., 2011)), accelerated erythroblast maturation in a manner similar to that observed in the bioreactor when exogenously dosed in to static culture. The equivalent concentration and inactivity of the endogenous cytokine in both culture systems initially suggested it was an unlikely candidate for either growth rate inhibition or total reduced proliferation in the bioreactor. However, mechanical forces as low as 40 pN can transiently activate TGF-β1 from its latent form; it is therefore reasonably probable that there is a bioreactor specific effect whilst stirring is applied causing accelerated maturation (Buscemi et al., 2011). Alternatively, or additionally, mechanical forces have been reported to have direct integrin mediated signalling effects that can influence cell maturation or inhibitory factor potency (Schwart, 2010). Although this could not explain the inhibition of proliferative rate (given the lack of substantive effect of TGF-β1 dosing into the bioreactor on proliferation rate), other unidentified inhibitory mediators are likely to be secreted. Mechanical agitation has been reported to increase cytokine release and signalling in a number of other cell types so there is evidence that such factors could be present at higher levels, or more potent, in a stirred bioreactor (Kurazumi et al., 2011).

A further limit to RBC production in vitro is the red cell yield per starting progenitor cell; the nature of the limit is either availability or cost of the required starting cells. The contribution of the starting cells to the cost of a final RBC product depends on the proliferative capacity of the cells during differentiation – every order of magnitude in cell expansion (approximately 3.3 population doublings) achieved between starting cells and final product reduces the requirement for (and hence the impact of the cost of) the starting cells by an order of magnitude on a per product basis. Conversely, the impact on cost of the final product for production of a given cell phenotype becomes exponentially larger as the cells proliferate towards terminal differentiation i.e. $2 \times 10^{12}$ terminally mature orthochromatic erythroblasts are required to make each unit of enucleated blood, but only $\sim 2 \times 10^8$ cells of the progenitor phenotype from ~14 PDs earlier in the process. This is important as differentiating cells have a changing profile of metabolism and other attributes that impact manufacturing productivity cost; in the case of red cells the potential to intensify would be anticipated to increase as the cells mature. The different approaches currently taken to overcome availability limitation of primary cells such as UCB – pluripotent, adult stem cell, engineered progenitor – will have different production costs that will be a function of cost of input cells and the subsequent proliferative capacity and intensification profile during differentiation; very recent progress to address both adult (vs. embryonic) maturation (Fujita et al., 2016) and yield (Giani et al., 2016) from renewable sources such as pluripotent cells has been promising. Our work has focused on erythroblast intensification because it will be a key determinant of process cost and practicality irrespective of the progenitor starting cell population due to both the exceptionally high number of these cells required in culture per unit of product and their proliferative capacity (Mercier Ythier, 2015). The data discussed here are therefore limiting and relevant for any candidate red cell manufacture process.

We conclude that there are no conventional barriers (shear stress sensitivity, O2 demand, or metabolic demand) that would prevent established bioreactor systems from producing blood at productivities under 100 l/unit, and possibly significantly higher. Further the effect of combined control of pH, oxygen, and mechanical agitation will greatly increase efficiency of final product harvest; in particular mechanical agitation, by rapidly increasing the proportion of enucleated cells, will enable peak enucleation to be engineered closer to peak culture system proliferation. This is absolutely key to reduce wastage of earlier enucleating cells, and to prevent challenging downstream processing of low purity enucleated product. However, the sensitivity of the cells to the bioprocess conditions adds risk and complexity as well as opportunity; mechanical stress may simultaneously increase enucleation whilst reducing total proliferative capacity, conventional biologics production strategies such as the addition of cell membrane protective agents appear to improve proliferation but reduce enucleation (presumably because membrane mechanics are critical for enucleation). To realize the potential efficiencies of production at suitably low risk, process scaling and intensification must be characterized for effects on all key elements of cell quality, and effort must be focused on identifying and mitigating the factor(s) that inhibit growth rate (and hence media efficiency).

**Key points**

- Enucleated red cells can be produced to high purity in industry standard stirred tank bioreactors at 500 l per unit of cells
- Mass transfer and common metabolites are not primary limitations indicating potential for substantially higher efficiency

**Conflict of interest disclosures**

No authors have any conflict of interest.

**Acknowledgements**

This work was funded by the Wellcome Trust (102610) and EPSRC (EP/K00705X/1). We would like to thank Lamin Marenah and Joanne Mountford of Glasgow University and SNBTS for carrying out HPLC haemoglobin analysis.
The productivity limit of manufactured blood cell therapy

References

Bourgeaux V, Lanao JM, Bax BE et al. 2016; Drug-loaded erythropoiesis: on the road toward marketing approval. Drug Deliv Dev Ther 10: 355–362.

Bozeman GJ. 2013; Survival of red blood cells after perfusion: processes and consequences. Front Physiol 4: 376.

Bosemi L, Ramonet D, Klingsberg F et al. 2011; The single-molecule mechanics of the latest TGF-β1 complex. Curr Biol 21(24): 2046–2054.

Chang CJ, Mitra K, Koya M et al. 2011; Production of embryonic and fetal-like red blood cells from human induced pluripotent stem cells. PLoS One 6(10): e25761.

Chiant Y. 2000; Animal-cell damage in sparged bioreactors. Trends Biotechnol 18(10): 420–432.

Chiant Y. 2001; Hydrodynamic damage to animal cells. Crit Rev Biotechnol 21(2): 67–110.

Dias J, Gumeniyuk M, Hyunchan K et al. 2011; Generation of red blood cells from human induced pluripotent stem cells. Stem Cells Dev 20(9): 1639–1647.

Endo T, Ishibashi Y, Okana H et al. 2016; The productivity limit of manufactured blood cell therapy. J Tissue Eng Regen Med 2016: 1255–1256.

Huss WT, Aulakh RP, Traud DL et al. 2012; Advanced microscale bioreactor system: a representative scale-down model for bench-top bioprocesses. Cytotechnology 64(6): 667–678.

Jin H, Kim H, Kim S et al. 2014; Erythropoietic potential of CD34+ hematopoietic stem cells from human cord blood and G-CSF-mobilized peripheral blood. Biomed Research International 2014: 435215.

Juiller H. 2004; Scale-up methodologies for Exscherichia cell and yeast fermentation processes. J Bisciot Bioeng 97(6): 347–364.

Kingsley PD, Malik J, Fantauzzo KA et al. 2004; Yolk sac-derived primitive erythroblasts enucleate during mammalian embryogenesis. Blood 104(1): 19–25.

Klockner W, Gacem R, Anderlitz T et al. 2013; Correlation between mass transfer coefficient and relevant operating parameters in cylindrical disposable shaken bioreactors on a bench-to-pilot scale. J Biol Eng 7(1): 28.

Kobari L, Yater S, Oudshiet N et al. 2012; Human induced pluripotent stem cells can reach complete terminal maturation in vivo and in vitro evidence in the erythropoietic differentiation model. Haematologica 97(12): 1795–1803.

Kurazumi H, Kubo M, Ohashi M et al. 2011; The Effects of Mechanical Stress on the Growth, Differentiation, and Paracrine Factor Production of Cardiac Stem Cells. PLOS One 6:28389.

Laplilonne H, Kobari L, Muxier C et al. 2010; Red blood cell generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica 95(10): 1651–1659.

Lee JC, Gimm JA, Lo AJ et al. 2004; Mechanism of protein sorting during erythroblast enucleation: role of cytoskeletal connectivity. Blood 103(5): 1912–1919.

Lu SJ, Feng Q, Park JS et al. 2008; Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 112(12): 4475–4484.

Luten MJ, Roodshonldol Sterewich B, Schaap NP et al. 2008; Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion 48(7): 1476–1485.

McAdams TH, Miller WM and Papenkaus ET. 1998; pH is a potent modulator of erythroid differentiation. Br J Haematol 103(2): 317–325.

Morch JY. 2015; Cultured blood versus donated blood: Long-run perspectives of the economy of blood. Biomed Mater Eng 25: 199–209.

Mihara K, Hiroysay T, Sudo K et al. 2006; Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells. Nat Biotechnol 24(10): 1255–1256.

Mikola M, Soro J and Amanullah A. 2007; Evaluation of a novel Wave Bioreactor cellbag for aerobic yeast cultivation. Bioprocess Biosyst Eng 30(4): 231–241.

Nelder-Nguyen TM, Wajchen J, Marden MC et al. 2002; Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol 20(5): 467–472.

Niewies AW, Rieley CD, Brosnan K et al. 2013; The physical characterisation of a microscale parallel bioreactor platform with an industrial CHO cell line expressing an IgG4. Bioeng J 76: 25–36.

Qiu C, Oliver EN, Velho M et al. 2008; Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood 111(4): 2400–2408.

Randell E, Glen KE, Workman VL et al. 2012; A novel automated bioreactor for scalable process optimisation of haematopoietic stem cell culture. J Biotechnol 163(3): 387–390.

Rousseau GF, Giarratana MC, and Douslay L. 2014; Large-scale production of red blood cells from stem cells: what are the technical challenges ahead? Biotechnol J 9(11): 28–38.

Ruffieux PA, Smockov UN and Marison IW. 1998; Measurement of volumetric (OUR) and determination of specific (QO2) O2 uptake rates in animal cell cultures. J Biotechnol 63(2): 85–95.

Sakakula O, Vartanovoa Po, Tanaka V et al. 2013; Enhanced erythrocyte cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis 51(2): 98–103.

Schweitzer MA. 2010; Integreins and Extracellular Matrix in Mechanotransduction. Cold Spring Harb Perspect Biol 2(12): a005066.

Thalmann T, Gheb H, Wuerz T et al. 2008; Plasminogen enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol 39(2): 167–177.

Timmers NE and Nielsen LK. 2009; Cell blood cell manufacture: current methods and future challenges. Trends Biotechnol 27(7): 415–422.

Xing X, Kerby BM, Li ZZ et al. 2009; Scale-up analysis for a CHO cell culture process in large-scale bioreactors. Biotechnol Bioeng 103(4): 733–746.

Zagari P, Jordan M, Stettler M et al. 2013; Lactate metabolism shift in CHO cell culture: the role of mitochondrial oxidative activity. N Biotechnol 30(2): 238–245.

Zeuner A, Martelli F, Vaglio S et al. 2012; Concise review: stem cell-derived erythropoiesis as upcoming players in blood transfusion. Stem Cells 30(8): 1587–1596.